Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL
J Clin Oncol. 2008 26 (6): 897-906

PMID: 18180460 · DOI:10.1200/JCO.2007.13.5939

PURPOSE - To administer the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib to patients with operable untreated breast cancer during the immediate preoperative period and to measure an antiproliferative and/or a proapoptotic effect in the post-therapy specimen and determine a biomarker profile associated with evidence of erlotinib-mediated cellular activity.

PATIENTS AND METHODS - Newly diagnosed patients with stages I to IIIA invasive breast cancer were treated with erlotinib 150 mg/d orally for 6 to 14 days until the day before surgery. Erlotinib plasma levels were measured by tandem mass spectrometry the day of surgery. Drug-induced changes in tumor cell proliferation and apoptosis were assessed by Ki67 immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling analysis, respectively, in biopsies from the pretherapy and surgical specimens. Biopsies were also evaluated for P-EGFR, P-HER-2, P-MAPK, P-Akt, P-S6, and S118 P-ER alpha.

RESULTS - In drug-sensitive PC9 xenografts, 5 days of treatment with erlotinib were enough to induce a maximal inhibition of cell proliferation and induction of apoptosis. Forty-one patients completed preoperative treatment with erlotinib. Grade
CONCLUSION - A presurgical approach to evaluate cellular responses to new drugs is feasible in breast cancer. EGFR inhibitors are worthy of testing against ER-positive breast cancers but are unlikely to have clinical activity against HER-2-positive or triple-negative breast cancers.

MeSH Terms (31)

Adult Aged Animals Antineoplastic Agents Biomarkers, Tumor Breast Neoplasms Cell Proliferation Chemotherapy, Adjuvant ErbB Receptors Erlotinib Hydrochloride Female Humans Immunohistochemistry In Situ Nick-End Labeling Ki-67 Antigen Mice Mice, Nude Middle Aged Neoadjuvant Therapy Neoplasms, Hormone-Dependent Neoplasm Staging Protein-Tyrosine Kinases Protein Kinase Inhibitors Quinazolines Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Signal Transduction Tandem Mass Spectrometry Treatment Outcome Xenograft Model Antitumor Assays

Connections (5)

This publication is referenced by other Labnodes entities: